Navigation Links
VolitionRx's Preliminary Diagnostic Clinical Trial Results Show High Sensitivity and Specificity for Colon, Breast and Lung Cancers
Date:11/5/2012

SINGAPORE, Nov. 5, 2012 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, today announced preliminary findings from its ongoing internal clinical trials of the NuQ® diagnostic platform. VolitionRx has analysed blood samples from 105 patients and was able to detect 76% of the patients with colon cancer, 96% of those with breast cancer, and 100% of patients with lung cancer.

Of the 105 patients tested, 74 had cancer (25 colon cancer, 25 breast cancer and 24 lung cancer), and 31 were healthy (not diagnosed with cancer). Volition tested all the patient samples for elevated nucleosome structures using one of its NuQ kits, with the following results for colon, breast and lung cancer:

  • Colon: 76% of cancers detected (19 of 25 patients) and 90% specificity (3 false positives from 31 healthy samples)
  • Breast: 96% of cancers detected (24 of 25 patients) and 90% specificity (3 false positives from 31 healthy samples)
  • Lung: 100% of cancers detected (24 of 24 patients) and 79% specificity (6 false positives from 28 healthy samples).

Further clinical results will be announced as they become available.

As announced in July, VolitionRx is currently moving through an independent 800-patient (expanded from the initial 400 patients) retrospective study on multiple cancer types, which is being carried out at Rheinische Friedrich-Wilhelms-Universitat Bonn and is expected to be completed by the end of this year. Preliminary results from this study based on 62 healthy subjects, 20 patients with benign colon tumors and 35 patients with colorectal cancer are consistent with VolitionRx internal results and indicate that Nucleosomics tests appear to differentiate cancer patients from patients with benign colon tumors as well as healthy patients.

Dr. Jake Micallef, Chief Scientific Officer for Belgian Volition, said: "Our internal results are extremely promising, and are consistent with independent data from external studies. Although these are early figures and the results will need to be validated over larger numbers of patient samples, it provides further validation that our Nucleosomics tests are effective at detecting certain types of cancers. We are reaching out to several universities to collaborate on further trials of larger numbers of several single cancers, in order to have enough data to apply for European regulatory approval."

Priv.-Doz. Dr Stefan Holdenrieder of Rheinische Friedrich-Wilhelms-Universitat Bonn, coordinator of the external trials, said: "I am encouraged by the data coming out of Volition's internal trial and our study here in Bonn. Given the results we have thus far, we will begin collecting patient blood samples for the 2,000 patient prospective trial focusing on twenty prevalent cancers."

Full data from both studies will be published in a peer-reviewed journal when the studies are complete.

Note on Preliminary Data
A test result is considered positive when above the normal range calculated by the standard diagnostic method (mean +/- 2 standard deviations of the mean).

About VolitionRx
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRx's development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

You can find more information about VolitionRx at our website at www.volitionrx.com, on Twitter at www.twitter.com/VolitionRx, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.

Safe Harbor Statement
Statements in this press release may be "forward-looking statements"Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE VolitionRx Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
2. Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
3. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
4. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
5. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
6. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
7. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
8. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
9. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):